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osting by EAbstract Both Helicobacter pylori (HP) and hepatitis C virus (HCV) infections are endemic in
Egypt. This work aimed to investigate the presence of HP in the liver of patients with chronic
hepatitis C (CHC) and explore the relation betweenHP infection, liver histopathology andHCV viral
load. The study included 60 patients with CHC. Virological, biochemical, liver biopsy and testing
for anti-Hp and anti-schistosomal antibodies in serum were done. Liver tissues were examined for
histopathological and presence of Hp by detection of HP 16S rRNA gene by PCR and sequence
analysis. Anti-schistosomal and anti HP antibody was found in 45% and 61.7%, respectively.
Low stages of ﬁbrosis (F0–F3) were found in 73.3% and advanced ﬁbrosis (F4–F6) in 26.7%.
HP DNA was found in 10% of the liver specimens. Although the frequency HP antibodies was
equally high in patients with advanced and low ﬁbrosis (68.8% and 59.1%, P> 0.05), the HP
DNA in liver tissue was signiﬁcantly more frequent in patients with advanced ﬁbrosis (31.25%
vs. 2.7%, P= 0.004). Meanwhile, the median viral load of HCV was higher in patients with HP
DNA in liver tissue compared to patients with no HP DNA in liver tissue (337.000 vs. 165.000,097184; fax: +20 226960650.
(L.A. Tag Eldeen).
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288 M.M. Ragheb et al.P= 0.3491). HCV RNA titer, ﬁbrosis score and history of blood transfusion, are independent fac-
tors associated with HP DNA in liver tissue. In conclusion, the presence of HP in liver tissue of
patients with advanced ﬁbrosis suggests a potential relation between HP infection and progression
of liver ﬁbrosis due to HCV.
ª 2011 Cairo University. Production and hosting by Elsevier B.V. All rights reserved.Introduction
Hepatitis C virus (HCV) is the major agent in non-A non-B
hepatitis with serious complications ranging from chronic
inﬂammatory disease to hepatic cirrhosis and end-stage liver
failure or hepatocellular carcinoma (HCC) [1]. Egypt has high
prevalence of hepatitis C, resulting in high morbidity and mor-
tality from liver disease. Approximately 12% of blood donors
are seropositive for HCV antibodies [2]. In a recent commu-
nity-based study, El-Zanaty and Way, reported positive
HCV RNA in sera of 9.8% of 1126 representative Egyptian
citizens [2].
The course of HCV related hepatic disease varies markedly
from one patient to another. Several factors including age at
exposure, duration of infection, alcohol intake, male gender,
viral immune response and steatosis have been shown to be
associated with ﬁbrosis progression [3].
However, even in the absence of these factors, disease pro-
gression may be observed in some patients, suggesting the role
of other factors. Host genetic factors or environmental factors,
such as a bacterial co-infection, could be involved [4]. It has
been observed that Helicobacter species were associated with
the pathogenesis of human enterohepatic diseases [5] The dis-
covery of the presence of Helicobacter species DNA in liver
material from patients with liver disease has led to the chal-
lenging hypothesis that these bacteria may play a role in the
evolution of hepatic lesions from chronic viral hepatitis to cir-
rhosis and HCC. Determinants of this evolution are not yet
fully understood, including those occurring in HCV positive
patients [6].
Meyer-ter-Vehn et al. documented that several Helicobacter
spp. could secrete a liver speciﬁc toxin that causes hepatocyte
necrosis in cell culture, and might therefore also be involved in
damaging liver parenchyma in vivo [7].
Concerning HCV liver diseases, HP and H. pullorum DNA
have been detected in the liver tissue of patients with chronic
hepatitis C (CHC) and HCC, suggesting that these bacteria
could be implicated in the progression of CHC to cirrhosis
and HCC [8].
Infection with HP is common in Egypt and acquisition of
infection occurs at a very young age [9]. A study carried on
Egyptian patients found that HP antibodies were found in
55.6% of HCV-infected patients vs. 39.4% of the healthy con-
trols. Moreover, the prevalence of HP infection was increased
signiﬁcantly from chronic active hepatitis to cirrhosis [10].
The association between HP infection and severity of
chronic liver diseases in patients with hepatitis C virus has been
documented in different parts of the world. However, no con-
clusive data is available in Egypt till now. These observations
promoted us to seek out the possible occurrence and associa-
tion of HP DNA with the pathological stages in liver among
CHC Egyptian patients.Patients and methods
This cross sectional descriptive study included 60 patients with
CHC, referred to the liver unit of Suez Canal University
Hospital to have a percutaneous liver biopsy, to evaluate suit-
ability for antiviral therapy with pegylated interferon/ribavi-
rin. Their ages ranged from 26 to 58 years.
Diagnosis of CHC was based on positivity to anti-HCV
antibodies, HCV RNA, either elevated or ﬂuctuating ALT
for more than 6 months, and/or bright liver by abdominal
ultrasonography. The study excluded patients co-infected with
HBV or HIV and patients with clinical or ultrasonographic
evidence of cirrhosis.
Sera were collected from each individual and stored
immediately at 20 C until use. Liver function tests,
alfa-fetoprotein (AFP), and anti-schistosomal antibodies were
measured using commercially available indirect haemaggluti-
nation assays (IHA) kits. The HCV RNA viral load was
quantiﬁed using Real Time PCR technique in an ABI
PRISM 7000 thermocycler (Applied Biosystems, Foster
City, CA). The serological and biochemical tests were done
in clinical pathology department and the molecular analysis
was performed at oncology diagnostic unit of Suez Canal
University Hospital. The study was approved by the Research
Ethics Committee of the Faculty of Medicine and informed
consents were obtained from each participant.Processing of liver tissues
Liver tissues were cut into two parts: one was formalin ﬁxed
and parafﬁn embedded for histo-pathological examination
and the second was immediately stored at 20 C until fur-
ther molecular analysis. Histo-pathological examination was
performed by faculty staff of pathology. Hepatic ﬁbrosis
staging was made according to Ishak scoring system [11].
Accordingly patients were divided a group of low ﬁbrosis
including F0–F3 and a group of advanced ﬁbrosis including
F4, F5 (incomplete cirrhosis) and F6 (complete cirrhosis).
According to the histological activity index patients were di-
vided into a group of minimal to mild activity (grades from 1
to 8) and a group of moderate to severe activity (grades from
9 to18) [12].
Detection of anti-HP antibody
Plasma samples were tested for anti-HP IgG antibody using a
commercial test kit, AccuBind ELISA Microwells (Mono-
bind Inc., Lake Forest, USA) according to the manufacturer’s
instruction. Results were considered positive when higher than
20 U/ml.
Detection of Helicobacter DNA from liver biopsy.
Table 1 Demographic and laboratory data of the studied
population (n= 60).
Age mean age ± SD (range) 42.98 ± 7.6 (26–58)
Gender (male/female) 45/15
PLT mean ± SD (range) 207 ± 175.48 (105–1480)
ALT mean ± SD (range) 59.60 ± 36.922 (17–187)
AST mean ± SD (range) 51.64 ± 24.820 (18–159)
Total bilirubin mean ± SD (range) 0.72 ± 0.26 (0.3–1.8)
direct bilirubin mean ± SD (range) 0.27 ± 0.15 (0-.8)
HCV PCR median (range) 165000 (327–7520,000)
AFP median (range) 2.3 (0.1–209)
Anti-Bilharzial Ab no (%) 27 (45%)
Anti-HP Ab no (%) 37 (61.7%)
Grade of chronic hepatitis C activity no (%)
Minimal to mild 49 (81.7%)
Moderate to severe 11 (18.3%).
Stage of ﬁbrosis no (%)
Low stage 44 (73.3%)
Advanced stage 16 (26.7%).
Fig. 1 Ampliﬁcation of a 480-bp 16S rRNA DNA of Helico-
bacter. Lane M: molecular size marker (100–1000 bp); lane 2, 4, 5:
positive samples; lane 6: negative control (double-distilled water).
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Genomic DNA was extracted from liver biopsy using Wiz-
ardSV Genomic DNA Puriﬁcation System (Promega Corpo-
ration, Madison, USA). DNA quantitation was performed
using the NanoDrop (ND)-1000 Spectrophotometer (Nano-
Drop Technologies Inc., Washington, USA). The extracted
DNA was stored in 20 C until used.
PCR ampliﬁcation
Nested PCR was performed with Helicobacter genus-speciﬁc
16S ribosomal RNA gene (16S rDNA) primers (Helinest-S &
R, Heli-S & R) which reported to amplify 26 species of Helico-
bacter genus [13].
First ampliﬁcation
The ampliﬁcation was carried out in a ﬁnal volume of 50 ll
reaction mixture containing: 1 lg DNA, 25 ll DreamT-
aqGreen PCR Master Mix (Fermentas, CA, USA), 50pM
Heli-nest-S primer: 50-ATTAGTGGCGCACGGGTGAGTA
A-30, 50pM Heli-nest-R primer: 50-TTTAGCATCCCGACTT
AAGGC-30.
The reaction mixture was initially denaturated at 94 C for
2 min, then ampliﬁed for 35 cycles as follow: Denaturation at
94 C for 30 s, annealing for 30 s at 55 C, extension at 72 C
for 11/2 min and ﬁnal extension at 72 C for 5 min in Robocy-
cler Gradiant 96 Thermo cycler (STRATAGEN, LA, USA).
Second ampliﬁcation
5ll of the ﬁrst ampliﬁcation product, 25 ll DreamTaqGreen
PCR Master Mix (Fermentas, CA, USA), 50pM Heli-S
primer: 50-GAACCTTACCTAGGCTTGACATTG-30, 50pM
Heli-R primer 50-GGTGAGTACAAGACCCGGGAA-30 was
ampliﬁed by following the same PCR condition as ﬁrst ampliﬁ-
cation step.
The ampliﬁed products were visualized on 2% ethidium
bromide stained agarose gel electrophoresis, the expected size
of product from second ampliﬁcation step was approximately
480 bp.60
H. pylori DNA +ve H. pylori DNA -veDNA sequencing
PCR products were sequenced as described [13]. The sequenc-
ing results were aligned and compared with known Helicobac-
ter species using Basic Local Alignment Search tool (BLAST;
National Center for Biotechnology Information).3 2 1
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Fig. 2 HP DNA in liver tissues according to severity of ﬁbrosis.Results
Demographic and laboratory data of 60 patients included in
this study were summarized in Table 1. Their mean age was
42.98 ± 7.6 and 56.7% of patients were between 41 and
50 years. The majority of patients were males (45/60).
Anti-HP antibody was present in 61.7% of patients, being
equally high among male and females (62.3% and 60%,
respectively). Helicobacter DNA was present in liver tissue of
6 out of 60 (10%) of studied patients, using Helicobacter genus
speciﬁc 16S rRNA gene primers, Fig. 1. The PCR products
Table 3 Distribution of HP DNA in liver tissues according to
stage of ﬁbrosis.
Stage of ﬁbrosis HP DNA +ve (no = 6)
Complete cirrhosis (F6) 1 (50%)
Incomplete cirrhosis (F5) 2 (28%)
Chronic hepatitis without cirrhosis
(F0–F4)
3 (6%)
26
18
1
43
11
5 5
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Fig. 3 HP Sero-reactivity and HP DNA in liver tissue of 60
patients in relation to ﬁbrosis staging.
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DNA positive cases were anti-HP antibodies positive. Most of
patients had low ﬁbrosis (44 of 60, 73.7%) and minimal to mild
activity of necroinﬂammation (49/60, 81.9%). Cirrhosis was
found in nine patients; incomplete cirrhosis (F5) in seven
and complete cirrhosis (F6) in two Table 3.
Although anti-HP was equally high in patients with low
and advanced ﬁbrosis with no statistically signiﬁcant difference
(59.1% and 68.8%, P= 0.496) Fig. 3, HP DNA in liver tissue
was signiﬁcantly more frequent in advanced ﬁbrosis (5/16,
31.25%) compared to low ﬁbrosis (1/44, 2.27%) (P= 0.004),
Tables 4 and 5 and Fig. 2.
Patients with HP DNA in liver tissue showed higher median
value of HCV RNA compared to patients with no HP DNA
(P = 0.3491), Table 2. Meanwhile the median viral load was
higher in patients with moderate to severe activity and patients
with advanced ﬁbrosis (286,000 and 192,500, respectively) com-
pared to patients withminimal tomild activity and patients with
low ﬁbrosis (108,000 and 135,000, respectively), Table 6.
Although of no signiﬁcance, higher values of ALT, AST and
AFP were found in patients with HP DNA in liver tissue com-
pared to the other group, Table 2. Interestingly, independent
factors associated with positive HP DNA (as dependent factor)
in liver tissues included history of blood transfusion
(OR= 100.5, 95% C.I. = 1.6–6176.8, P= 0.028), advanced
ﬁbrosis score (OR = 4.19, 95% C.I. = 1.4–12.52, P= 0.01)Table 2 Comparison of laboratory data regarding presence of HP
Laboratory data HP DNA (in liver tissue)
Positive (no = 6)
Median (range)
HCV RNA titre 337,000 (51,200–7520,000)
Platelets 168,500 (11,000–236,000)
ALT 57 (17–143)
AST 58 (22–90)
Albumin 4.6 (4.1–5.1)
PT 12.7 (12.1–15.2)
T. Bilirubin 0.75 (0.5–1.8)
D. Bilirubin 0.25 (0.1–0.4)
AFP 3.5 (0.5–32.9)
Statistically signiﬁcant (P< 0.05).
a Kruskal-Wallis test.and high HCV RNA viral titer (OR = 1.0, 95% C.I. = 1.0–
1.0, P= 0.044) Table 7.
Anti-schistosomal antibodies were found in 45% of
patients, 66.7% of them had anti-HP antibodies and only
3.7% had HP DNA in liver tissues Table 8.
Discussion
Previous studies showed that DNA from HP – and
H. pullorum-like organisms were present in the liver of cir-
rhotic patients with or without HCC due to HCV, suggesting
that Helicobacter species could be a co-morbid factor for dis-
ease progression [6]. In this study, we demonstrated the pres-
ence, Helicobacter DNA using genus-speciﬁc 16S rRNA gene
primers in liver tissue of 10% of the studied patients.
Interestingly, the gene sequence obtained from positive
Helicobacter species speciﬁc 16S rRNA PCR was analogous
to HP and not similar to H. hepaticus, found in mouse liver tu-
mors [14], or to species previously found in the biliary tract of
humans, such as H. pullorum, H. bilis, and H. Rappini [15].
This ﬁnding encourages the speculation that the presence of
Helicobacter DNA in human liver tissue might reﬂect the
transport of HP of gastric origin or its DNA to the liver [13]
and that intestinal Helicobacter might be implicated in hepa-
tobiliary disease [16].
In this study, although anti HP was equally high in patients
with low and advanced ﬁbrosis with no signiﬁcant difference,
HP DNA in liver tissue was signiﬁcantly associated with HCV
related advanced hepatic ﬁbrosis. It was present in 33.3% of pa-
tients with cirrhosis and 5.9% with no cirrhosis. This ﬁnding is
comparable to 41.6% and 17% as reported by Caste´ra et al. [4]
and 68%and 3.5%as reported byRocha et al. [6] respectively in
cirrhotic and non cirrhotic patients. Other similar studies have
reported the association between HP DNA in liver tissue andDNA in liver tissue.
P-value
Negative (no = 54)
Median (range)
165,000 (327–7,060,000) 0.3491a
170,000 (105,000–336,000) 0.9803a
47 (22–187) 0.5962a
42 (18–159) 0.4159a
4.3 (3–5.1) 0.0979a
12.8 (11.2–15.5) 0.9409a
0.7 (0.3–1.3) 0.3974a
0.28 (0.02–0.8) 0.9388a
2.2 (0.1–33.7) 0.7115a
Table 4 HP sero-reactivity and HP DNA in liver tissue of patients with low and advanced stage of ﬁbrosis.
HP infection Stage of ﬁbrosis P-value
Low (no = 44) Advanced (no = 16)
No (%) No (%)
HP Ab sero-positive 26 (59.1) 11 (68.8) (0.496)c
HP Ab sero-negative 18 (40.9) 5 (31.2)
HP DNA positive in liver 1 (2.3) 5 (31.2) (0.004)ab
HP DNA negative in liver 43 (97.7) 11 (68.8)
a Statistically signiﬁcant (P< 0.05).
b Fisher’s exact test.
c Chi-square test.
Table 5 Relation between the grades of chronic hepatitis C
and HP DNA in liver tissue.
HP DNA HAI scoring grade P-value
Minimal/mild (49) Moderate/severe (11)
No (%) No (%)
Positive 3 (6.1%) 3 (27.3) 0.068a
Negative 46 (93.9%) 8 (72.7)
Statistically signiﬁcant (P< 0.05).
a Fisher’s exact test.
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[10–19]. This association might be explained by increased colo-
nization of HP in the liver of patients with chronic hepatitis C
and advanced ﬁbrosis. Otherwise, infection of the liver with
HP acts as a co-factor in promoting ﬁbrogenesis [6] particularly
when the HCV RNA load is high. This hypothesis agreed with
that of Fagoonee et al. who supposed that co-infectionTable 6 HCV RNA viral load in the studied patients according to
HCV RNA ran
Min to mild activity (no = 49) 327–7520,000
Mod to severe activity (no = 11) 51,200–2320,63
Low ﬁbrosis (no = 44) 560–7520,000
Advanced ﬁbrosis (no = 16) 327–2320,436
Statistically signiﬁcant (P< 0.05).
a Kruskal-Wallis test.
Table 7 Multiple logistic regression analysis for independent facto
patients with chronic hepatitis C.
Beta Stand
Constant 0.237 3.295
Blood transfusion (reference: no) 4.61 2.101
HCV RNR titre (reference: low viral load < 400,000) 0.006 0.003
Stages of ﬁbrosis (reference: low ﬁbrosis) 1.434 0.558
Dependent variable: (HP DNA +ve = 1, HP DNA ve = 0).
Excluded variables: Gender, residence, surgery, dental extraction, smokin
time, T. Bilirubin, D. Bilirubin, AFP. HP antibody, HP PCR, degree of
a Statistically signiﬁcant (P< 0.05).with HP or Helicobacter species might amplify the chronic
inﬂammation of liver parenchyma, thereby leading to cirrhosis
and HCC [20].
Chronic hepatitis is an inﬂammatory disease, characterized
by increased levels of pro-inﬂammatory cytokines such as
interleukins 1, 6 (IL-1, IL-6), tumor necrosis factor (TNF)
and by the presence of lympho-mono cellular inﬁltrate and
lymphoid follicle formation [21]. Viruses such as HCV are only
capable of limited inﬂammation, due to shedding of IL-1
receptor in circulation, thereby limiting the possibility of
IL-1 binding to cellular receptors [22]. Helicobacters, on the
other hand, are strong inducers of the inﬂammatory cascade
[23] infection with them could lead to the accumulation of
extraordinary number of lymphocytes and polymorphonuclear
cells in the infected tissue [24].
It is worth noting that the lower prevalence of HP DNA in
liver specimens of cirrhotic patients in this study compared to
Rocha et al. [6] is possibly due to the difference in the severity
of liver disease in both studies. The cohort of Rocha and col-
leges included patients with chronic hepatitis and cirrhosisthe stages of ﬁbrosis and grades of chronic hepatitis C.
ge Median P-value
108,000 0.1906a
4 286,000
135,500 0.5418a
192,500
rs associated with detection of HP DNA in liver tissues of 60
ard error P-value Odds ratio 95.0% C.I. for odds ratio
Lower Upper
0.943 1.268
0.028a 100.5 1.6 6176.8
0.044a 1.000 1.000 1.000
0.010a 4.194 1.404 12.528
g, DM, HTN, schistosomal titre, platelet count, ALT, prothrombin
cirrhosis.
Table 8 HCV RNA viral load and stage of ﬁbrosis in patients positive and negative for anti-schistosomal antibody.
Anti-schistosomal Ab P value
Positive (no = 27) Negative (no = 33)
HCV RNA (IU/ml)
Range 377–7060,000 4320–7520,000 0.73a
Median 225,000 138,000
Stage of ﬁbrosis (F0–F6)
Range F0–F5 F1–F6 0.78a
Median 3 2
HP DNA positive no (%) 1 (3.7) 5 (15.2) 0.15b
HP DNA negative no (%) 26 (96.3) 28 (84.8)
HP Ab positive no (%) 18 (66.7) 14 (42.4) 0.47c
HP Ab negative no (%) 9 (33.3) 19 (57.6)
Statistically signiﬁcant (P< 0.05).
a Kruskal-Wallis test.
b Fisher’s exact test.
c Chi-square test.
292 M.M. Ragheb et al.with and without hepatocellular carcinoma. In this study, all
the studied patients were diagnosed clinically as chronic hepa-
titis and only 9 of them had cirrhosis (incomplete in 7 and
complete in 2). In all there were no stigmata of portal hyper-
tension, or decompensation.
The presence of HP in liver tissue could occur via a retro-
grade route from the duodenum or through the portal circula-
tion. Rocha et al. suggested that the presence of Helicobacter
could be the consequence of structural changes in the liver
namely, intrahepatic shunts; when cirrhosis occurs [6]. How-
ever, this does not explain the existence of HP in liver specimens
in 3 of 51 patients with non cirrhotic ﬁbrosis and representing
50% of all patients with HP in liver tissue. In this setting, a ret-
rograde route, from the duodenum to the liver might be the
underlying mechanism for HP to colonize in liver tissue. It is
worth noting that all patients with HP in liver were seropositive
for anti-HP antibodies and patients negative for HP DNA in
liver tissue were also negative to anti-HP antibodies. This result
is similar to that reported by Petrenkiene¨ et al. [25].
In this study, patients with HP DNA in liver tissue showed
higher median value of HCV RNA compared to patients with
no HP DNA. Meanwhile the median viral load was higher in
patients with moderate to severe activity and patients with ad-
vanced ﬁbrosis compared to patients with minimal to mild
activity and patients with low ﬁbrosis.
Although the explanation of these ﬁndings is difﬁcult, the
association of HP DNA in liver tissue with high serum HCV
RNA load could play a synergistic role in enhancing cytotoxic
immune response and promoting ﬁbrosis in patients with
CHC. This hypothesis is opposed by the absence of association
between viral load and disease severity or progression in pa-
tients with chronic liver disease related to HCV in studies tar-
geting the natural history of HCV infection [26–29].
It is worth noting that, history of blood transfusion, high
HCV RNA viral load and advanced stage of ﬁbrosis were sig-
niﬁcantly associated as independent risk factors with presence
of HP DNA in liver tissues (P = 0.028, P = 0.044, P= 0.01,
respectively). Up to our knowledge, no data concerning these
factors and presence of HP DNA in liver tissues are available
in the literature.
This study revealed a higher median stage of ﬁbrosis and
HCV viral load in patients positive for anti- schistosomal anti-
body compared to negative patients. However, the differencewas statistically not signiﬁcant. Although non signiﬁcant, anti
HP antibodies was more frequent in patients positive to anti-
schistosomal Ab compared to negative patients (P= 0.47).
This results are consistent with the results of El-Masry et al.
study in which, In HCV-infected patients, the concurrent schis-
tosoma infection was documented largely in anti-HP-positive
patients [10]. On the other hand, in the anti- schistosomal anti-
body positive group only 1/27 patient was positive for HP
DNA in liver tissue compared to 5/33 of the other group.
The higher viremia and stage of ﬁbrosis found in patients po-
sitive to anti-schistosomal antibody was associated with a low
detection of HP DNA in liver tissue. Although the explanation
is difﬁcult, it is suggested that patients concomitantly infected
with schistosomiasis and HCV may had an intense inﬂamma-
tory reaction leading to less colonization of HP in liver tissue
[30].
Limitation of this study is the small number of the study
subjects and the inability to obtain normal liver tissue to exam-
ine for the presence of HP DNA. Therefore, further study on a
larger sample size to validate the impact of infection with HP
on the outcomes chronic hepatitis C and examine the possibil-
ity of ﬁnding HP DNA in normal liver tissues. Also to study
the molecular similarity between hepatic and gastric HP in
specimens from the gastric mucosa.Acknowledgments
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